Merit Medical Systems R&D Spending Growth & History (MMSI)
Merit Medical Systems's r&d spending was $97.4M for fiscal 2025.
View full Merit Medical Systems company overviewMerit Medical Systems annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $97.4M | $9.9M | +11.30% |
| 2024 | 2024-12-31 | $87.5M | $4.7M | +5.73% |
| 2023 | 2023-12-31 | $82.7M | $7.2M | +9.56% |
| 2022 | 2022-12-31 | $75.5M | $4.3M | +5.98% |
| 2021 | 2021-12-31 | $71.2M | $13.7M | +23.83% |
| 2020 | 2020-12-31 | $57.5M | −$8.1M | −12.31% |
| 2019 | 2019-12-31 | $65.6M | $6.1M | +10.22% |
| 2018 | 2018-12-31 | $59.5M | $8.1M | +15.81% |
| 2017 | 2017-12-31 | $51.4M | $6.2M | +13.65% |
| 2016 | 2016-12-31 | $45.2M | $4.4M | +10.83% |
| 2015 | 2015-12-31 | $40.8M | $4.2M | +11.41% |
| 2014 | 2014-12-31 | $36.6M | $2.7M | +8.10% |
| 2013 | 2013-12-31 | $33.9M | $6.1M | +21.91% |
| 2012 | 2012-12-31 | $27.8M | $5.9M | +26.70% |
| 2011 | 2011-12-31 | $21.9M | $6.6M | +43.06% |
| 2010 | 2010-12-31 | $15.3M | $4.2M | +37.31% |
| 2009 | 2009-12-31 | $11.2M | — | — |
Merit Medical Systems quarterly r&d spending
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $25.4M | $1.0M | +4.19% |
| Q1 2026 | 2026-03-31 | $22.6M | $131,000 | +0.58% |
| Q4 2025 | 2025-12-31 | $26.5M | $1.3M | +5.35% |
| Q3 2025 | 2025-09-30 | $24.0M | $3.4M | +16.75% |
| Q2 2025 | 2025-06-30 | $24.4M | $4.1M | +20.25% |
| Q1 2025 | 2025-03-31 | $22.5M | $996,000 | +4.64% |
| Q4 2024 | 2024-12-31 | $25.2M | $3.6M | +16.43% |
| Q3 2024 | 2024-09-30 | $20.5M | $881,000 | +4.48% |
| Q2 2024 | 2024-06-30 | $20.3M | $134,000 | +0.67% |
| Q1 2024 | 2024-03-31 | $21.5M | $168,000 | +0.79% |
| Q4 2023 | 2023-12-31 | $21.6M | $1.2M | +5.89% |
| Q3 2023 | 2023-09-30 | $19.6M | $425,000 | +2.21% |
| Q2 2023 | 2023-06-30 | $20.1M | $1.7M | +9.01% |
| Q1 2023 | 2023-03-31 | $21.3M | $3.9M | +22.59% |
| Q4 2022 | 2022-12-31 | $20.4M | $30,000 | +0.15% |
| Q3 2022 | 2022-09-30 | $19.2M | $2.2M | +13.24% |
| Q2 2022 | 2022-06-30 | $18.5M | $873,000 | +4.96% |
| Q1 2022 | 2022-03-31 | $17.4M | $1.1M | +6.84% |
| Q4 2021 | 2021-12-31 | $20.4M | $5.3M | +34.84% |
| Q3 2021 | 2021-09-30 | $17.0M | $3.5M | +25.68% |
| Q2 2021 | 2021-06-30 | $17.6M | $3.6M | +25.43% |
| Q1 2021 | 2021-03-31 | $16.3M | $1.4M | +9.43% |
| Q4 2020 | 2020-12-31 | $15.1M | −$1.1M | −6.89% |
| Q3 2020 | 2020-09-30 | $13.5M | −$3.5M | −20.49% |
| Q2 2020 | 2020-06-30 | $14.0M | −$2.3M | −14.12% |
| Q1 2020 | 2020-03-31 | $14.9M | −$1.2M | −7.30% |
| Q4 2019 | 2019-12-31 | $16.3M | $884,000 | +5.75% |
| Q3 2019 | 2019-09-30 | $17.0M | $2.5M | +16.95% |
| Q2 2019 | 2019-06-30 | $16.3M | $1.0M | +6.63% |
| Q1 2019 | 2019-03-31 | $16.0M | $1.7M | +12.02% |
| Q4 2018 | 2018-12-31 | $15.4M | $2.6M | +20.76% |
| Q3 2018 | 2018-09-30 | $14.5M | $1.7M | +13.14% |
| Q2 2018 | 2018-06-30 | $15.3M | $2.0M | +15.05% |
| Q1 2018 | 2018-03-31 | $14.3M | $1.8M | +14.35% |
| Q4 2017 | 2017-12-31 | $12.7M | $939,000 | +7.97% |
| Q3 2017 | 2017-09-30 | $12.8M | $1.4M | +12.38% |
| Q2 2017 | 2017-06-30 | $13.3M | $1.9M | +16.48% |
| Q1 2017 | 2017-03-31 | $12.5M | $1.9M | +18.29% |
| Q4 2016 | 2016-12-31 | $11.8M | $367,000 | +3.21% |
| Q3 2016 | 2016-09-30 | $11.4M | $909,000 | +8.64% |
| Q2 2016 | 2016-06-30 | $11.4M | $2.2M | +24.20% |
| Q1 2016 | 2016-03-31 | $10.6M | $916,000 | +9.47% |
| Q4 2015 | 2015-12-31 | $11.4M | $1.9M | +19.93% |
| Q3 2015 | 2015-09-30 | $10.5M | $1.8M | +21.03% |
| Q2 2015 | 2015-06-30 | $9.2M | −$439,000 | −4.55% |
| Q1 2015 | 2015-03-31 | $9.7M | $892,000 | +10.16% |
| Q4 2014 | 2014-12-31 | $9.5M | $701,000 | +7.95% |
| Q3 2014 | 2014-09-30 | $8.7M | $1.4M | +18.88% |
| Q2 2014 | 2014-06-30 | $9.6M | $993,000 | +11.48% |
| Q1 2014 | 2014-03-31 | $8.8M | −$328,000 | −3.60% |
| Q4 2013 | 2013-12-31 | $8.8M | $1.2M | +15.09% |
| Q3 2013 | 2013-09-30 | $7.3M | $210,000 | +2.96% |
| Q2 2013 | 2013-06-30 | $8.6M | $2.1M | +31.21% |
| Q1 2013 | 2013-03-31 | $9.1M | $2.7M | +41.41% |
| Q4 2012 | 2012-12-31 | $7.7M | $1.6M | +25.84% |
| Q3 2012 | 2012-09-30 | $7.1M | $1.7M | +31.42% |
| Q2 2012 | 2012-06-30 | $6.6M | $1.1M | +20.67% |
| Q1 2012 | 2012-03-31 | $6.4M | $1.5M | +29.23% |
| Q4 2011 | 2011-12-31 | $6.1M | — | — |
| Q3 2011 | 2011-09-30 | $5.4M | $1.5M | +39.74% |
| Q2 2011 | 2011-06-30 | $5.5M | $1.7M | +45.96% |
| Q1 2011 | 2011-03-31 | $5.0M | — | — |
| Q3 2010 | 2010-09-30 | $3.9M | — | — |
| Q2 2010 | 2010-06-30 | $3.7M | — | — |
Merit Medical Systems r&d spending trends
Over the last five fiscal years, Merit Medical Systems's r&d spending increased from $57.5M to $97.4M, a change of $39.8M. The latest reported quarter, Q2 2026, shows $25.4M.
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Merit Medical Systems source filings ↗